Citations

Clear

6 citation(s) found for "Barwick, Benjamin G".

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes
Yamashita, Yusuke, Patton, Jonathan, Shotts, Yuliza, Du, Megan, Sharik, Meaghen, Pfeffer, Kirsten, Zhu, Yuan, Shi, Chang-Xin, Stein, Caleb, Meermeier, Erin, Chesi, Marta, Xiao, Lanbo, Chinnaiyan, Arul, Barwick, Benjamin, Bergsagel, P. Leif, Yamashita, Yusuke , Yamashita, Yusuke , Yamashita, Yusuke, Patton, Jonathan, Shotts, Yuliza, Du, Megan, Sharik, Meaghen, Pfeffer, Kirsten, Zhu, Yuan, Shi, Chang-Xin, Stein, Caleb, Meermeier, Erin, Chesi, Marta, Xiao, Lanbo, Chinnaiyan, Arul, Barwick, Benjamin, Bergsagel, P. Leif

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2138-2138

10.1182/blood-2025-2138 Get It

Abstract Introduction: Despite remarkable advances in treatment, patients with multiple myeloma (MM) continue to suffer relapse. Therefore, the development of novel therapeutic strategies is required. The SWI/SNF chromatin remodeling complex, especially its core ATPase subunits SMARCA2/4, is essential for super-enhancer function and MM cell survival. Furthermore, NSD2, which is overexpressed in t(4;14)-positive MM, has been reported to interact with SMARCA2/4, suggesting differential sensitivity to SMARCA2/4 inhibition. While ATPase inhibitors and PROTAC degraders targeting SMARCA2/4 have demonstrated promising preclinical efficacy in MM and other malignancies, their broader therapeutic relevance remains to be clarified. Methods: To support the clinical development of mSWI/SNF antagonists for MM, we first performed PRISM-based profiling of the anti-proliferative effects of both an mSWI/SNF ATPase PROTAC degrader and a catalytic inhibitor across a panel of 888 cancer cell lines from diverse lineages. Lineage enrichment analysis identified plasma cell myeloma as one of the most sensitive malignancies, with the PROTAC degrader demonstrating particularly potent effects. These were followed by in-depth studies in 35 human myeloma cell lines (HMCLs) using FHD-286 (SMARCA2/4 ATPase inhibitor), AU-24118 (CRBN-based degrader), and AU-15330 (VHL-based degrader). Cell viability was assessed after 5-day treatment by flow cytometry with Annexin V and Live/Dead staining. Additional assays were performed in hCRBN-engineered murine plasmacytoma cell lines and Vk*MYChCRBN MM mouse models. Chromatin profiling employed CUT&Tag with SMARCA2/4 and IKZF1/3 antibodies. Results: FHD-286 and AU-24118 showed potent anti-myeloma activity across most cell lines (median IC₅₀: 4.5 nM and 5.9 nM, respectively). HMCLs with t(4;14), as compared to those without, were more sensitive to FHD-286 (p= 0.0064), with a similar trend for AU-24118 (p=0.09). AU-24118 log2 IC₅₀ values correlated with those of FHD-286 (r=0.62, p=0.0002) and with pomalidomide (r=0.61, p=0.0002), suggesting a shared biology. Indeed, CUT&Tag analysis for SMARCA2/4 and the pomalidomide targets IKZF1/3 showed these factors co-localized at most sites throughout the genome in MM.1S cells, including at DUSP22/IRF4, POU2AF1, and IgH super-enhancers. Treatment with AU-15330, depleted SMARCA2/4 off chromatin at >80% of sites within 8 hours (FDR <0.01), and somewhat surprisingly also depleted IKZF1/3 off chromatin at 70% of bound regions, indicating IKZF1/3 function is dependent upon SWI/SNF. Resultantly, combination studies of SWI/SNF targeting agents and pomalidomide showed a lack of synergy and in some cases antagonism, highlighting the importance of careful evaluation when considering combination with pomalidomide. We and others have demonstrated that murine cells are IMiDs resistant due to species-specific differences in CRBN. Using three distinct mouse plasmacytoma cell lines (+/-hCRBN), hCRBN-expressing cells showed a 100-fold greater sensitivity to AU-24118 compared hCRBN- cell lines. In vivo safety testing of AU-24118 using hCRBN transgenic mice exhibited early mortality within 7 days at doses ≥1.875 mpk and within 3 days at doses ≥7.5 mpk, accompanied by rapid body weight loss. In contrast, a preliminary efficacy study using de novo Vk*MYChCRBN mice, AU-24118 administered at 1 mpk three times per week was well tolerated and led to approximately 40% reduction in serum M-protein within 2 weeks (p<0.05), with no notable weight loss, demonstrating a therapeutic window. Conclusions: Broad PRISM profiling confirms lineage-specific vulnerability of MM to SWI/SNF inhibition, with in vitro and in vivo validation supporting selective efficacy in high-risk t(4;14)-positive subtypes. FHD-286, AU-15330, and AU-24118 demonstrated strong in vitro activity, particularly in t(4;14)-positive HMCLs. This activity was due, in part, to chromatin compaction and decommissioning of lineage and oncogenic enhancers as well as eviction of IKZF1/3 off chromatin. AU-24118 showed high selectivity, with picomolar range IC₅₀ in sensitive HMCLs. Due to species-specific CRBN differences, accurate toxicity evaluation of AU-24118 requires hCRBN-expressing models, and preliminary data indicate in vivo efficacy in the highly predictive Vk*MYChCRBN model. These findings support the potential of SMARCA2/4 targeting agents, especially AU-24118, as promising therapies for MM, particularly in high-risk t(4;14)-positive cases.
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Neri, Paola , Barwick, Benjamin G. , Jung, David , Patton, Jonathan C. , Maity, Ranjan , Tagoug, Inès , Stein, Caleb K. , Tilmont, Rémi , Leblay, Noémie , Ahn, Sungwoo , Lee, Holly , Welsh, Seth J. , Flynt, Erin , Thakurta, Anjan , Bergsagel, P. Leif , Bergsagel, P. Leif , Riggs, Daniel L , Stong, Nicholas , Flynt, Erin , Thakurta, Anjan , Keats, Jonathan J , Lonial, Sagar , Boise, Lawrence H , Bahlis, Nizar Jacques , Barwick, Benjamin G , Stein, Caleb K , Neri, Paola , Riggs, Daniel L. , Stong, Nicholas , Keats, Jonathan J. , Lonial, Sagar , Boise, Lawrence

Mayo Clinic

Blood Cancer Discovery | November 7, 2023 | Volume: 5 | Issue: 1 | Pages: 56-73

10.1158/2643-3230.bcd-23-0061 | PMID 37934799 Get It

Abstract Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanisms are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted chromatin-bound IKZF1, but eviction of P300 and BRD4 coactivators only occurred in IMiD-sensitive cells. IKZF1-bound enhancers overlapped other transcription factor binding motifs, including ETV4. Chromatin immunoprecipitation sequencing showed that ETV4 bound to the same enhancers as IKZF1, and ETV4 CRISPR/Cas9-mediated ablation resulted in sensitization of IMiD-resistant MM. ETV4 expression is associated with IMiD resistance in cell lines, poor prognosis in patients, and is upregulated at relapse. These data indicate that ETV4 alleviates IKZF1 and IKZF3 dependency in MM by maintaining oncogenic enhancer activity and identify transcriptional plasticity as a previously unrecognized mechanism of IMiD resistance. Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by maintaining MYC and other oncogenes. These data implicate transcription factor redundancy as a previously unrecognized mode of IMiD resistance in MM. See related article by Welsh, Barwick, et al., p. 34. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Welsh, Seth J. , Barwick, Benjamin G. , Meermeier, Erin W. , Riggs, Daniel L. , Shi, Chang-Xin , Zhu, Yuan Xiao , Sharik, Meaghen E. , Du, Megan T. , Rocha, Leslie D. Abrego , Garbitt, Victoria M. , Meurice, Nathalie , Alvarado, Yuliza Tafoya , Todd, Kennedi T. , Brown, Sochilt , Hammond, Zachery J., Cuc, Nicklus H. , Wittenberg, Courtney , Herzog, Camille , Roschke, Anna V. , Demchenko, Yulia N. , Chen, Wei-dong D. , Li, Peng , Liao, Wei , Leonard, Warren J. , Chesi, Marta , Bergsagel, P. Leif , Bergsagel, P. Leif , Abrego Rocha, Leslie D , Stein, Caleb K , Petit, Joachim L , Meurice, Nathalie , Tafoya Alvarado, Yuliza , Fonseca, Rodrigo , Todd, Kennedi T , Brown, Sochilt , Hammond, Zachery J , Cuc, Nicklus H , Wittenberg, Courtney , Herzog, Camille , Roschke, Anna V , Demchenko, Yulia N , Chen, Wei-Dong D , Li, Peng , Leonard, Warren J , Lonial, Sagar , Bahlis, Nizar Jacques , Neri, Paola , Boise, Lawrence H , Chesi, Marta , Barwick, Benjamin G , Riggs, Daniel L , Meermeier, Erin W , Stein, Caleb K. , Petit, Joachim L. , Fonseca, Rodrigo , Lonial, Sagar , Neri, Paola , Boise, Lawrence

Mayo Clinic

Blood Cancer Discovery | September 28, 2023 | Volume: 5 | Issue: 1 | Pages: 34-55

10.1158/2643-3230.bcd-23-0062 | PMID 37767768 Get It

Abstract Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. Significance: These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM. See related article by Neri, Barwick, et al., p. 56. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4
Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma
Welsh, Seth J. , Garbitt, Victoria M. , Du, Megan T. , Todd, Kennedi T. , Hammond, Zachary J., Brown, Sochilt , Boise, Larry H., Kuehl, W. Michael, Chesi, Marta , Riggs, Daniel L. , Meermeier, Erin W. , Shi, Chang-Xin , Sharik, Meaghen E. , Stein, Caleb K. , Neri, Paola , Bahlis, Nizar Jacques , Barwick, Benjamin G. , Bergsagel, P. Leif

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 1593-1593

10.1182/blood-2021-147551 Get It

Abstract Multiple myeloma (MM) is an incurable form of plasma cell cancer in which primary and secondary chromosomal translocations routinely juxtapose oncogenes to plasma cell-specific super-enhancers. Coincidentally, drugs which target super-enhancers have had success clinically. For example, immunomodulatory imide drugs (IMiDs) degrade super-enhancer-binding pioneer factors IKAROS and AIOLOS, while glucocorticoids (Dexamethasone) and proteasome inhibitors (Bortezomib) have the ability to transrepress or block the processing of super-enhancer-forming NF-κB proteins, respectively. Currently, alternative enhancer-targeting drugs are also in clinical development, like p300 inhibitors which target the acetyl-binding bromodomains and/or histone acetyl transferase activity of the chromatin-regulating coactivator homologs CBP and EP300. Despite showing therapeutic promise, our understanding of how these drugs function, alone or together, remains incomplete. Case in point, we find that IMiD-induced degradation of its target proteins IKAROS and AIOLOS does not guarantee a therapeutic response in vitro, and patients successfully treated with IMiDs eventually relapse; meanwhile, coactivator-targeting therapies like p300 inhibitors are often too toxic in vivo, and lack a therapeutic window. To improve the outcomes of MM patients we need to understand the heterogeneous genetics and transcription-factor milieus of the myeloma enhancer landscape, as well as how to increase the precision of enhancer-disrupting drugs. To accomplish this, our lab utilizes more than 60 human myeloma cell lines that have been extensively characterized at the genetic, proteomic, and drug-therapeutic-response levels. Additionally, we have generated a highly-predictive immunocompetent mouse model (Vk*MYC hCRBN+) that develops human-like MM and is sensitive to both IMiDs and a new class of therapeutics termed "degronimids" (normal mice do not respond to IMiDs or degronimids). Our central hypothesis is that combining a broad coactivator-targeting drug (e.g., the p300 inhibitor GNE-781), with a MM-specific transcription factor-targeting drug (e.g., IMiDs) restricts toxicities to myeloma cells and thus improves the therapeutic window. Currently, we are testing a variety of coactivator-targeting compounds alongside traditional IMiD therapies and other preclinical transcription factor-targeting drugs both in vivo and in vitro. We show that Vk*MYC hCRBN+ mice are exquisitely sensitive to GNE-781, requiring one fourth of the dose needed to treat other cancers and therefore avoiding the neutropenia and thrombocytopenia seen at higher doses. Second, we show that although IMiDs and GNE-781 induce an effective but transient response in vivo as single agents, the combination of the two drugs proved curative, with a progressive deepening of the anti-tumor response occurring even after therapy is discontinued. Ongoing experiments aim to determine how this drug combination, and other coactivator + transcription factor-targeting combinations, permanently disrupt myeloma-specific super-enhancers. Disclosures Neri: BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Bahlis: Sanofi: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Genentech: Consultancy. Boise: AstraZeneca: Honoraria, Research Funding; AbbVie/Genentech: Membership on an entity's Board of Directors or advisory committees. Chesi: Abcuro: Patents & Royalties: Genetically engineered mouse model of myeloma; Pi Therapeutics: Patents & Royalties: Genetically engineered mouse model of myeloma; Pfizer: Consultancy; Novartis: Consultancy, Patents & Royalties: human CRBN transgenic mouse; Palleon Pharmaceuticals: Patents & Royalties: Genetically engineered mouse model of myeloma.
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia
Kaushal, Akhilesh , Carr, Allison R. , Pendleton, Katherine E. , Barwick, Benjamin G. , Manalo, Renee Julia , McCachren, Samuel S. , Gupta, Vikas A. , Joseph, Nisha S. , Hofmeister, Craig C. , Heffner, Leonard T., Ansell, Stephen M. , Dhodapkar, Kavita M. , Dhodapkar, Madhav V. , Pendleton, Katherine E , Barwick, Benjamin G , Manalo, Julia , McCachren, Samuel S , Gupta, Vikas A , Hofmeister, Craig C , Kaufman, Jonathan L , Ansell, Stephen M , Boise, Lawrence H , Dhodapkar, Kavita M , Nooka, Ajay K. , Kaufman, Jonathan L. , Boise, Lawrence , Lonial, Sagar

Mayo Clinic

Blood Cancer Discovery | September 1, 2021 | Volume: 2 | Issue: 6 | Pages: 600-615

10.1158/2643-3230.bcd-21-0043 | PMID 34778800 Get It

Abstract Waldenstrom macroglobulinemia (WM) and its precursor IgM gammopathy are distinct disorders characterized by clonal mature IgM-expressing B-cell outgrowth in the bone marrow. Here, we show by high-dimensional single-cell immunogenomic profiling of patient samples that these disorders originate in the setting of global B-cell compartment alterations, characterized by expansion of genomically aberrant extrafollicular B cells of the nonmalignant clonotype. Alterations in the immune microenvironment preceding malignant clonal expansion include myeloid inflammation and naïve B- and T-cell depletion. Host response to these early lesions involves clone-specific T-cell immunity that may include MYD88 mutation–specific responses. Hematopoietic progenitors carry the oncogenic MYD88 mutations characteristic of the malignant WM clone. These data support a model for WM pathogenesis wherein oncogenic alterations and signaling in progenitors, myeloid inflammation, and global alterations in extrafollicular B cells create the milieu promoting extranodal pattern of growth in differentiated malignant cells. Significance: These data provide evidence that growth of the malignant clone in WM is preceded by expansion of extrafollicular B cells, myeloid inflammation, and immune dysfunction in the preneoplastic phase. These changes may be related in part to MYD88 oncogenic signaling in pre–B progenitor cells and suggest a novel model for WM pathogenesis. This article is highlighted in the In This Issue feature, p. 549